Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Bigpharma - The Top 50
Chapter 3 - Most active bigpharma dealmakers
- 3.1 Bigpharma M&A activity
- 3.2 Bigpharma partnering
Chapter 4 - Top bigpharma deals - 2000-6
- 4.1 Bigpharma M&A
- 4.2 Bigpharma partnering
Chapter 5 - Bigpharma Agreements
- 5.1 How to use bigpharma agreements
- 5.2 What should an agreement contain?
- 5.3 Deal type definitions
- 5.4 Company agreement listings
- Abbott
- Actavis
- Akzo Nobel (Organon)
- Allergan
- Altana
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Bayer Schering Pharma AG
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono KGaA
- Mitsubishi
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Roche
- Sanofi-Aventis
- Schering Plough
- Serono
- Shionogi Seiyaku
- Shire
- Solvay
- Takeda
- Tanabe Seiyaku
- TAP Pharmaceuticals
- Teva
- UCB
- Watson
- Wyeth
Chapter 6 - Resources
Appendices
- Appendix 1 - Example development and license contract document
- Appendix 2 - Example M&A contract document
About CurrentPartnering
Recent report titles from CurrentPartnering
Order Form - Reports
Order form - Company Dealmaking Profiles
Order Form - Report Update Subscription
Order Form - CD-Rom
TABLE OF FIGURES
- Figure 1: Bigpharma - top 50 by pharma revenues 2006
- Figure 2: Additional bigpharma companies profiled in report
- Figure 3: Leading Bigpharma M&A companies, 2005-6
- Figure 4: Leading Bigpharma partnering companies, 2005-6
- Figure 5: Leading M&A deals by value, 2005-6
- Figure 6: Leading partnering deals by value, 2005-6
- Figure 7: Checklist of key contract agreement clauses in a partnering
agreement
- Figure 8: Deal type definitions
- Figure 9: Online partnering resources
- Figure 10: Development and license agreement between Boehringer Ingelheim
and Inspire Pharmaceuticals, February 2006
- Figure 11: Agreement and plan of merger between Johnson & Johnson and
Guidant Corporation
|
Related Report
|
View Cart
